Validation of serum versus plasma measurements of chromogranin A levels in patients with carcinoid tumors: Lack of correlation between absolute chromogranin A levels and symptom frequency

Pancreas

Volumn 33, Issue 3, 2006, Pages 250-254

  Woltering, Eugene A ^a,c,h   Hilton, Ruth S ^b   Zolfoghary, Christy M ^a   Thomson, Jessica ^c   Zietz, Stanley ^d   Go, Vay Liang W ^e   Vinik, Aaron I ^f   Vinik, Etta ^f   O'Dorisio, Thomas M ^g   Mamikunian, Gregg ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Inter Science Institute   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF THE SCIENCES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h NONE   (United States)

Author keywords

Carcinoid; Carcinoid syndrome; Chromogranin A; Neuroendocrine tumors; Octreotide; Plasma and serum

Indexed keywords

CHROMOGRANIN A; OCTREOTIDE;

ANALYTICAL PARAMETERS; ARTICLE; CARCINOID SYNDROME; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; FLUSHING; FREQUENCY ANALYSIS; HUMAN; HYPOTHESIS; INFORMATION PROCESSING; LINEAR SYSTEM; LONG TERM CARE; MEASUREMENT; MEDICAL INFORMATION; PATIENT MONITORING; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; VALIDATION PROCESS;

EID: 33749154697     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000235302.73615.d4     Document Type: Article

References (17)

1. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62(suppl A):33-38.
2. Søndenaa K, Sen J, Heinle F, et al. Chromogranin A, a marker of the therapeutic success of neuroendocrine liver metastases: preliminary report. World J Surg. 2004;28(9):890-895.
3. Kölby L, Bernhardt P, Swärd C, et al. Chromogranin A as a determinant of midgut carcinoid tumor volume. Regul Pept. 2004;120(1-3):269-273.
4. Fykse V, Sandvik AK, Qvigstad G, et al. Treatment of enterochromagranin cell carcinoids with octreotide LAR. Scand J Gastroenterol. 2004;39(7):621-628.
5. D'Herbomez M, Gouze V. Chromogranin A: a marker of neuroendocrine tumors. Annales de Biologie Unique. 2002;60(6):641-646.
6. Öberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966-973.
7. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors: a consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394-424.
8. Ramage JK, Davies AHG, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(suppl IV):iv1-iv16.
9. Clark O, Ajani J, Benson A III, et al. Neuroendocrine Tumors. National Comprehensive Cancer Network Practice Guidelines in Oncology. Version 1. 2005, 3/29/05.
10. Feldman SA, Eiden LE. The chromogranins: Their role in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol. 2003;14(1):3-23.
11. Woltering EA, Mamikunian PM, Zietz S, et al. The effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas. 2005;31(4):392-400.
12. Calhoun K, Toth-Fejel S, Cheek J, et al. Serum peptide profiles in patients with carcinoid tumors. Am J Surg. 2003;186(1):28-31.
13. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of Chromogranin A for diagnosis and follow up of endocrine tumours. Clin Endocrinol (Oxf). 2004;60(5):644-652.
14. Pape UF, Hocker M, Seuss U, et al. New molecular aspects in the diagnosis and therapy of neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res. 2000;153:45-60.
15. Tartaglia A, Bianchini S, Vezzadini P. Biochemical diagnosis of gastroenteropancreatic endocrine tumors. Minerva Med. 2003;94(1):1-7.
16. Desai DC, O'Dorisio TM, Schirmer W, et al. Serum pacreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept. 2001;96:113-117.
17. Rohaizak M, Farndon JR. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumors. ANZ J Surg. 2002;72(9):635-638.